CN111701032A - 兼具药物控释及成像功能的介孔氧化硅复合体的制备方法 - Google Patents

兼具药物控释及成像功能的介孔氧化硅复合体的制备方法 Download PDF

Info

Publication number
CN111701032A
CN111701032A CN202010584377.1A CN202010584377A CN111701032A CN 111701032 A CN111701032 A CN 111701032A CN 202010584377 A CN202010584377 A CN 202010584377A CN 111701032 A CN111701032 A CN 111701032A
Authority
CN
China
Prior art keywords
msio
solution
nanoparticles
stirring
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010584377.1A
Other languages
English (en)
Inventor
房慧颖
蒋伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chongqing University Cancer Hospital
Original Assignee
Chongqing University Cancer Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing University Cancer Hospital filed Critical Chongqing University Cancer Hospital
Priority to CN202010584377.1A priority Critical patent/CN111701032A/zh
Publication of CN111701032A publication Critical patent/CN111701032A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/183—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an inorganic material or being composed of an inorganic material entrapping the MRI-active nucleus, e.g. silica core doped with a MRI-active nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/225—Microparticles, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/05—Metallic powder characterised by the size or surface area of the particles
    • B22F1/054—Nanosized particles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/07—Metallic powder characterised by particles having a nanoscale microstructure
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F9/00—Making metallic powder or suspensions thereof
    • B22F9/16—Making metallic powder or suspensions thereof using chemical processes
    • B22F9/18—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds
    • B22F9/24—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Acoustics & Sound (AREA)
  • General Chemical & Material Sciences (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Manufacturing & Machinery (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种兼具药物控释及成像功能的介孔氧化硅复合体的制备方法，如下步骤：(1)Au/Fe3O4@mSiO2‑SH分子探针的制备；首先，制备Au纳米颗粒；其次，制备Au/Fe3O4壳核结构纳米颗粒；然后，应用反相微乳液法制备Au/Fe3O4@mSiO2‑SH纳米颗粒；(2)Au/Fe3O4@mSiO2/DOX‑SS‑PEG‑HA的制备；DOX乙醇溶液中加入Au/Fe3O4@mSiO2‑SH纳米颗粒，所得纳米颗粒分散于DMSO水溶液，加入SH‑PEG‑NH2，获得纳米粒子Au/Fe3O4@mSiO2/DOX‑SS‑PEG‑NH2；然后采用碳二亚胺法将HA溶于MES溶液，加入EDC和NHS作为偶联剂，加入的Au/Fe3O4@mSiO2/DOX‑SS‑PEG‑NH2。本发明的纳米探针具有MRI、MPI及PAI三种成像功能和化疗及光热治疗功能，可实现对肿瘤的全面、灵敏、靶向性成像，并能进行药物疗效的实时定量在体监测，在分子水平为肿瘤的精准诊疗开辟了全新领域。

Description

兼具药物控释及成像功能的介孔氧化硅复合体的制备方法
技术领域
本发明属于纳米材料与分子医学技术领域，具体涉及一种复合介孔二氧化硅纳米药物载体及其制备方法。
背景技术
随着肿瘤诊断和治疗技术的提高，精准治疗及监测治疗反应对于提高疗效越来越重要。目前临床常用的肿瘤诊断和评估方法主要有CT、磁共振(MRI)、超声等，但存在敏感性及特异性低、不能实时监测等缺点。多模态影像技术可以克服现有手段的局限性，实现无创、实时、定量、特异性检测，提供更加全面精确的信息并指导治疗。化疗是抗肿瘤治疗的重要手段，但传统化疗存在副反应大，缺乏靶向性，易产生多药耐药以及治疗方式单一等缺点。近年来，光热治疗、靶向治疗、纳米药物控释等研究领域的发展，为解决以上问题提供了新的思路。
目前，吴春英等人发明的药物载体及其制备方法和药物组合物及其应用(CN103893764A)，该发明将金纳米棒包裹介孔二氧化硅装载药物，利用近红外激光激发后实现药物释放和热疗。但由于金纳米粒子不具有磁性，不能进行无创的磁粒子实时药物监测，难以进行疗效实时监控；且药物控释需借助激光激发，实施复杂，实际应用中存在难度。
发明内容
针对现有技术中存在的上述不足，本发明提供了一种兼具药物控释及成像功能的介孔氧化硅复合体的制备方法。
为了解决上述技术问题，本发明采用了如下技术方案：
兼具药物控释及成像功能的介孔氧化硅复合体的制备方法，该方法包括如下步骤：
(1)Au/Fe3O4@mSiO2-SH分子探针的制备
首先，Au纳米颗粒的制备：将1ml HAuCl4·4H2O(1wt％)溶液和2ml柠檬酸三钠(38.8mM)溶液溶于超纯水(90ml)中，磁力搅拌1分钟；然后缓慢加入1～2mL NaBH4溶液(0.075wt％)，继续搅拌，直到溶液变成酒红色，不再变化；经超纯水三次洗涤后获得Au纳米颗粒；
其次，制备Au/Fe3O4壳核结构纳米颗粒：将100mg的氨基修饰的四氧化三铁(Fe3O4-NH2)纳米颗粒分散于100mL纯水中，加入1～1.5ml Au纳米粒子溶液(10mg/ml)，室温下搅拌2小时后经磁性分离，用去离子水洗涤三次，加入1～2ml 0.1M的HAuCl4·4H2O和10ml 0.2M羟胺水溶液，反应2小时后，将所得纳米粒子经磁性分离，用去离子水洗涤三次，即成功制备Au/Fe3O4壳核结构纳米颗粒；
然后，应用反相微乳液法制备Au/Fe3O4@mSiO2-SH纳米颗粒：取0.1g上述制备粒子分散到30mL超纯水中，超声30min，分散均匀后倒入三口烧瓶中，加入50mL水，40mL乙醇，1.5mL氨水，0.2～0.3mL正硅酸四乙酯(TEOS)，搅拌反应10～12h后，然后加入75mg十六烷基三甲基溴化铵(CTAB)，搅拌1h，加入1mL氨水，搅拌10min，混合均匀后，缓慢加入TEOS乙醇溶液，再加入0.01～0.02mL 3-巯丙基三乙氧基硅烷(MPTES)，搅拌反应12h后将产物磁分离，用乙醇洗涤三次以除去多余的TEOS和少量的CTAB；然后在80℃的盐酸乙醇溶液回流搅拌12h，萃取3次，除去粒子中的模板剂CTAB，即可制备得到Au/Fe3O4@mSiO2-SH纳米颗粒；
(2)Au/Fe3O4@mSiO2/DOX-SS-PEG-HA的制备
将30～40mg/mL DOX乙醇溶液或紫杉醇(TAX)乙醇溶液中加入30mgAu/Fe3O4@mSiO2-SH纳米颗粒，搅拌2h，同时防止乙醇挥发，搅拌后，离心分离，将所得纳米颗粒分散于20％DMSO水溶液，超声分散30min后，加入25mgSH-PEG-NH2，反应5h后，离心分离，即可获得纳米粒子Au/Fe3O4@mSiO2/DOX-SS-PEG-NH2；然后采用碳二亚胺法将50mg的HA溶于PH＝5的2mL MES溶液，加入30mg的EDC和20mg的NHS作为偶联剂在室温下活化激活1h，随后缓慢加入50mg的Au/Fe3O4@mSiO2/DOX-SS-PEG-NH2，调节PH至8，反应4h后离心，去离子水洗涤三次，即得多功能靶向药物控释分子探针Au/Fe3O4@mSiO2/DOX-SS-PEG-HA。
进一步，含荧光(FITC)Au/Fe3O4@mSiO2-SH纳米颗粒，在加入MPTES时，同时加入0.1-0.2mL 3-氨丙基三乙氧基硅烷(APTES)-异硫氰酸荧光素(FITC)反应前体。
进一步，在步骤(1)中，氨水的质量分数28％。
进一步，在步骤(1)中，TEOS乙醇溶液为0.2～0.3ml TEOS分散于20mL乙醇所形成的溶液。
与现有技术相比，本发明具有如下优点：
1、本发明通过整合多种成像方式实现肿瘤诊断及体内药物监控，并减少多药耐药获得高效精准治疗，达到肿瘤多模态诊断、监测疗效及多种治疗方式协同治疗的目的。
2、本发明将结合传统磁共振技术与新兴磁粒子成像、光声成像手段，实现多模态成像及疗效实时定量检测；并实现光热及化学协同治疗；并利用细胞内部氧化还原反应实现药物控释。
3、构建高效、特性强、灵敏度高、无创的多功能靶向药物控释分子探针；以Au/Fe3O4为核，以介孔二氧化硅为载体，制备壳核结构纳米颗粒，以CD44受体为靶点，合成多功能靶向分子探针，对其靶向能力、成像效果及脏器分布进行深入研究，实现肿瘤早期精确诊断多模态成像(磁共振成像、磁粒子成像、光声成像)及体内各脏器药物定量分布监测。
4、壳核结构介孔二氧化硅孔道内封装化疗药物，其表面以二硫键连接PEG-透明质酸实现体内长循环及可控性释放。联合激光照射Au纳米粒子实现光热治疗与化疗的协同治疗。
5、本发明提出了一种新的集靶向诊疗为一体的多模态纳米探针的概念，该纳米探针具有MRI、MPI及PAI三种成像功能，可实现对肿瘤的全面、灵敏、靶向性成像，并能进行药物疗效的实时定量在体监测，在分子水平为肿瘤的精准诊疗开辟了全新领域。
6、本发明构建了多种功能相结合的且具有临床转化前景的创新型靶向诊疗分子探针。采用的Au粒子可以进行光热治疗；Fe3O4可实现多种成像及实时疗效监控；介孔二氧化硅可以封装药物并增强Fe3O4的MRI成像信号；二氧化硅表面修饰的SS-PEG-HA，实现了靶向化疗药物控释及延长体内循环。
7、药物靶向控释系统为解决化疗药物限制性毒性问题提供了新的解决思路。光热治疗与化疗相结合，起到协同增效作用，促进肿瘤多学科治疗的发展。
具体实施方式
下面结合具体实施方式对本发明作进一步详细地描述。
实施例1
本实施例1提供了一种兼具药物控释及成像功能的介孔氧化硅复合体的制备方法，该方法包括以下步骤：
(1)Au/Fe3O4核的制备
Fe3O4纳米颗粒的制备。将1g FeCl3·6H2O和0.37g FeCl2·4H2O用20mL通氮除氧去离子水混合；取130mL去离子水在250mL的圆底烧瓶中通氮除氧，加入12.5mL的浓度为25-28％的浓氨水，在剧烈搅拌下迅速向其中倒入上述的铁盐混合溶液，在氮气条件下反应l h(80℃)；反应完毕后，用永磁铁从反应溶液分离Fe3O4磁性纳米粒子，用甲醇洗涤三次，分散在50mL甲苯中。然后，将(3-氨基丙基)三甲氧基硅烷(APTES)(25μL)加入到12.5mL上述Fe3O4溶液中，超声分散30min，在60℃下反应4h后，用磁场分离，甲醇洗涤三次，除去多余的APTMS和甲苯，分散在甲醇中。
Au纳米颗粒的制备。将1ml HAuCl4·4H2O(1wt％)溶液和2ml柠檬酸三钠(38.8mM)溶液溶于超纯水(90ml)中，磁力搅拌1分钟；然后缓慢加入1mL NaBH4溶液(0.075wt％)，继续搅拌，直到溶液变成酒红色，不再变化；经超纯水三次洗涤后获得Au纳米颗粒。
Au/Fe3O4壳核结构纳米颗粒的制备。将100mg的氨基修饰的四氧化三铁(Fe3O4-NH2)纳米颗粒分散于100mL纯水中，加入1ml Au纳米粒子溶液(10mg/ml)，室温下搅拌2小时后经磁性分离，用去离子水洗涤三次，加入1ml0.1M的HAuCl4·4H2O和10ml 0.2M羟胺水溶液，反应2小时后，将所得纳米粒子经磁性分离，用去离子水洗涤三次，即成功制备Au/Fe3O4壳核结构纳米颗粒。
(2)Au/Fe3O4@mSiO2-SH纳米颗粒的制备
取0.1g上述制备粒子分散到30mL超纯水中，超声30min，分散均匀后倒入三口烧瓶中，加入50mL水，40mL乙醇，1.5mL氨水(质量分数28％)，0.2mL正硅酸四乙酯(TEOS)，搅拌反应10h后，然后加入75mg十六烷基三甲基溴化铵(CTAB)，搅拌1h，加入1mL氨水，搅拌10min，混合均匀后，缓慢加入TEOS乙醇溶液(0.2ml TEOS分散于20mL乙醇)，再加入0.01mL 3-巯丙基三乙氧基硅烷(MPTES)，搅拌反应12h后将产物磁分离，用乙醇洗涤三次以除去多余的TEOS和少量的CTAB；然后在盐酸乙醇溶液(80℃)回流搅拌12h，萃取3次，除去粒子中的模板剂CTAB，即可制备得到Au/Fe3O4@mSiO2-SH纳米颗粒。
(3)Au/Fe3O4@mSiO2/DOX-SS-PEG-HA的制备
将30mg/mL阿霉素(DOX)乙醇溶液中加入30mg Au/Fe3O4@mSiO2-SH纳米颗粒，搅拌2h(同时防止乙醇挥发)后，离心分离，将所得纳米颗粒分散于20％DMSO水溶液，超声分散30min后，加入25mg SH-PEG-NH2，反应5h后，离心分离，即可获得纳米粒子Au/Fe3O4@mSiO2/DOX-SS-PEG-NH2。然后采用碳二亚胺法将HA(50mg)溶于2mL MES溶液(PH＝5)，加入EDC(30mg)和NHS(20mg)作为偶联剂在室温下活化激活1h，随后缓慢加入50mg的Au/Fe3O4@mSiO2/DOX-SS-PEG-NH2，调节PH至8，反应4h后离心，去离子水洗涤三次，即得多功能靶向药物控释分子探针Au/Fe3O4@mSiO2/DOX-SS-PEG-HA。
该兼具药物控释及成像功能的介孔二氧化硅复合体，具体是指：Au/Fe3O4纳米颗粒作为内核实现磁共振成像、磁粒子成像及光声成像，同时Au纳米颗粒在激光照射下实现光热治疗；壳层介孔二氧化硅纳米孔道内封装多柔比星(DOX)，其表面修饰二硫键-PEG，PEG可用于在运输过程中密封药物及延长体内循环时间，在靶向肿瘤细胞后，利用二硫桥骨架结构在肿瘤细胞内的谷胱甘肽作用下进行氧化还原反应实现药物胞内控释。
实施例2
本实施例2提供了一种兼具药物控释及成像功能的介孔氧化硅复合体的制备方法，该方法包括以下步骤：
(1)Au/Fe3O4核的制备
Fe3O4纳米颗粒的制备。将1g FeCl3·6H2O和0.37g FeCl2·4H2O用30mL通氮除氧去离子水混合；取160mL去离子水在250mL的圆底烧瓶中通氮除氧，加入15mL的浓度为25-28％的浓氨水，在剧烈搅拌下迅速向其中倒入上述的铁盐混合溶液，在氮气条件下反应2h(80℃)；反应完毕后，用永磁铁从反应溶液分离Fe3O4磁性纳米粒子，用甲醇洗涤三次，分散在60mL甲苯中。然后，将(3-氨基丙基)三甲氧基硅烷(APTES)(20μL)加入到12.5mL上述Fe3O4溶液中，超声分散30min，在60℃下反应4h后，用磁场分离，甲醇洗涤三次，除去多余的APTMS和甲苯，分散在甲醇中。
Au纳米颗粒的制备。将1ml HAuCl4·4H2O(1wt％)溶液和2ml柠檬酸三钠(38.8mM)溶液溶于超纯水(90ml)中，磁力搅拌1分钟；然后缓慢加入2mL NaBH4溶液(0.075wt％)，继续搅拌，直到溶液变成酒红色，不再变化；经超纯水三次洗涤后获得Au纳米颗粒。
Au/Fe3O4壳核结构纳米颗粒的制备。将100mg的氨基修饰的四氧化三铁(Fe3O4-NH2)纳米颗粒分散于100mL纯水中，加入1.5ml Au纳米粒子溶液(10mg/ml)，室温下搅拌2小时后经磁性分离，用去离子水洗涤三次，加入2ml0.1M的HAuCl4·4H2O和10ml 0.2M羟胺水溶液，反应2小时后，将所得纳米粒子经磁性分离，用去离子水洗涤三次，即成功制备Au/Fe3O4壳核结构纳米颗粒。
(2)Au/Fe3O4@mSiO2-SH纳米颗粒的制备
取0.1g上述制备粒子分散到30mL超纯水中，超声30min，分散均匀后倒入三口烧瓶中，加入50mL水，40mL乙醇，1.5mL氨水(质量分数28％)，0.3mL正硅酸四乙酯(TEOS)，搅拌反应12h后，然后加入75mg十六烷基三甲基溴化铵(CTAB)，搅拌1h，加入1mL氨水，搅拌10min，混合均匀后，缓慢加入TEOS乙醇溶液(0.3ml TEOS分散于20mL乙醇)，再加入0.02mL 3-巯丙基三乙氧基硅烷(MPTES)，搅拌反应12h后将产物磁分离，用乙醇洗涤三次以除去多余的TEOS和少量的CTAB；然后在盐酸乙醇溶液(80℃)回流搅拌12h，萃取3次，除去粒子中的模板剂CTAB，即可制备得到Au/Fe3O4@mSiO2-SH纳米颗粒。
(3)Au/Fe3O4@mSiO2/DOX-SS-PEG-HA的制备
将40mg/mL阿霉素(DOX)乙醇溶液中加入30mg Au/Fe3O4@mSiO2-SH纳米颗粒，搅拌2h(同时防止乙醇挥发)后，离心分离，将所得纳米颗粒分散于20％DMSO水溶液，超声分散30min后，加入25mg SH-PEG-NH2，反应5h后，离心分离，即可获得纳米粒子Au/Fe3O4@mSiO2/DOX-SS-PEG-NH2。然后采用碳二亚胺法将HA(50mg)溶于2mL MES溶液(PH＝5)，加入EDC(30mg)和NHS(20mg)作为偶联剂在室温下活化激活1h，随后缓慢加入50mg的Au/Fe3O4@mSiO2/DOX-SS-PEG-NH2，调节PH至8，反应4h后离心，去离子水洗涤三次，即得多功能靶向药物控释分子探针Au/Fe3O4@mSiO2/DOX-SS-PEG-HA。
实施例3
本实施例3提供了一种兼具药物控释及成像功能的介孔氧化硅复合体的制备方法，该方法包括以下步骤：
(1)Au/Fe3O4核的制备
Fe3O4纳米颗粒的制备。将1g FeCl3·6H2O和0.37g FeCl2·4H2O用20mL通氮除氧去离子水混合；取130mL去离子水在250mL的圆底烧瓶中通氮除氧，加入12.5mL的浓度为25-28％的浓氨水，在剧烈搅拌下迅速向其中倒入上述的铁盐混合溶液，在氮气条件下反应l h(80℃)；反应完毕后，用永磁铁从反应溶液分离Fe3O4磁性纳米粒子，用甲醇洗涤三次，分散在50mL甲苯中。然后，将(3-氨基丙基)三甲氧基硅烷(APTES)(25μL)加入到12.5mL上述Fe3O4溶液中，超声分散30min，在60℃下反应4h后，用磁场分离，甲醇洗涤三次，除去多余的APTMS和甲苯，分散在甲醇中。
Au纳米颗粒的制备。将1ml HAuCl4·4H2O(1wt％)溶液和2ml柠檬酸三钠(38.8mM)溶液溶于超纯水(90ml)中，磁力搅拌1分钟；然后缓慢加入1mL NaBH4溶液(0.075wt％)，继续搅拌，直到溶液变成酒红色，不再变化；经超纯水三次洗涤后获得Au纳米颗粒。
Au/Fe3O4壳核结构纳米颗粒的制备。将100mg的氨基修饰的四氧化三铁(Fe3O4-NH2)纳米颗粒分散于100mL纯水中，加入1ml Au纳米粒子溶液(10mg/ml)，室温下搅拌2小时后经磁性分离，用去离子水洗涤三次，加入1ml0.1M的HAuCl4·4H2O和10ml 0.2M羟胺水溶液，反应2小时后，将所得纳米粒子经磁性分离，用去离子水洗涤三次，即成功制备Au/Fe3O4壳核结构纳米颗粒。
(2)Au/Fe3O4@mSiO2-SH纳米颗粒的制备
取0.1g上述制备粒子分散到30mL超纯水中，超声30min，分散均匀后倒入三口烧瓶中，加入50mL水，40mL乙醇，1.5mL氨水(质量分数28％)，0.2mL正硅酸四乙酯(TEOS)，搅拌反应10h后，然后加入75mg十六烷基三甲基溴化铵(CTAB)，搅拌1h，加入1mL氨水，搅拌10min，混合均匀后，缓慢加入TEOS乙醇溶液(0.2ml TEOS分散于20mL乙醇)，再加入0.01mL 3-巯丙基三乙氧基硅烷(MPTES)，搅拌反应12h后将产物磁分离，用乙醇洗涤三次以除去多余的TEOS和少量的CTAB；然后在盐酸乙醇溶液(80℃)回流搅拌12h，萃取3次，除去粒子中的模板剂CTAB，即可制备得到Au/Fe3O4@mSiO2-SH纳米颗粒。
(3)Au/Fe3O4@mSiO2/TAX-SS-PEG-HA的制备
将30mg/mL紫杉醇(TAX)乙醇溶液中加入30mg Au/Fe3O4@mSiO2-SH纳米颗粒，搅拌2h(同时防止乙醇挥发)后，离心分离，将所得纳米颗粒分散于20％DMSO水溶液，超声分散30min后，加入25mg SH-PEG-NH2，反应5h后，离心分离，即可获得纳米粒子Au/Fe3O4@mSiO2/TAX-SS-PEG-NH2。然后采用碳二亚胺法将HA(50mg)溶于2mL MES溶液(PH＝5)，加入EDC(30mg)和NHS(20mg)作为偶联剂在室温下活化激活1h，随后缓慢加入50mg的Au/Fe3O4@mSiO2/TAX-SS-PEG-NH2，调节PH至8，反应4h后离心，去离子水洗涤三次，即得多功能靶向药物控释分子探针Au/Fe3O4@mSiO2/TAX-SS-PEG-HA。
最后说明的是，以上实施例仅用以说明本发明的技术方案而非限制，尽管参照较佳实施例对本发明进行了详细说明，本领域的普通技术人员应当理解，可以对本发明的技术方案进行修改或者等同替换，而不脱离本发明技术方案的宗旨和范围，其均应涵盖在本发明的权利要求范围当中。

Claims (4)

1.兼具药物控释及成像功能的介孔氧化硅复合体的制备方法，其特征在于，该方法包括如下步骤：
(1)Au/Fe3O4@mSiO2-SH分子探针的制备
首先，Au纳米颗粒的制备：将1ml HAuCl4·4H2O(1wt％)溶液和2ml柠檬酸三钠(38.8mM)溶液溶于超纯水(90ml)中，磁力搅拌1分钟；然后缓慢加入1～2mL NaBH4溶液(0.075wt％)，继续搅拌，直到溶液变成酒红色，不再变化；经超纯水三次洗涤后获得Au纳米颗粒；
其次，制备Au/Fe3O4壳核结构纳米颗粒：将100mg的氨基修饰的四氧化三铁(Fe3O4-NH2)纳米颗粒分散于100mL纯水中，加入1～1.5ml Au纳米粒子溶液(10mg/ml)，室温下搅拌2小时后经磁性分离，用去离子水洗涤三次，加入1～2ml 0.1M的HAuCl4·4H2O和10ml 0.2M羟胺水溶液，反应2小时后，将所得纳米粒子经磁性分离，用去离子水洗涤三次，即成功制备Au/Fe3O4壳核结构纳米颗粒；
然后，应用反相微乳液法制备Au/Fe3O4@mSiO2-SH纳米颗粒：取0.1g上述制备粒子分散到30mL超纯水中，超声30min，分散均匀后倒入三口烧瓶中，加入50mL水，40mL乙醇，1.5mL氨水，0.2～0.3mL正硅酸四乙酯(TEOS)，搅拌反应10～12h后，然后加入75mg十六烷基三甲基溴化铵(CTAB)，搅拌1h，加入1mL氨水，搅拌10min，混合均匀后，缓慢加入TEOS乙醇溶液，再加入0.01～0.02mL 3-巯丙基三乙氧基硅烷(MPTES)，搅拌反应12h后将产物磁分离，用乙醇洗涤三次以除去多余的TEOS和少量的CTAB；然后在80℃的盐酸乙醇溶液回流搅拌12h，萃取3次，除去粒子中的模板剂CTAB，即可制备得到Au/Fe3O4@mSiO2-SH纳米颗粒；
(2)Au/Fe3O4@mSiO2/DOX-SS-PEG-HA的制备
将30～40mg/mL DOX乙醇溶液或紫杉醇(TAX)乙醇溶液中加入30mgAu/Fe3O4@mSiO2-SH纳米颗粒，搅拌2h，同时防止乙醇挥发，搅拌后，离心分离，将所得纳米颗粒分散于20％DMSO水溶液，超声分散30min后，加入25mg SH-PEG-NH2，反应5h后，离心分离，即可获得纳米粒子Au/Fe3O4@mSiO2/DOX-SS-PEG-NH2；然后采用碳二亚胺法将50mg的HA溶于PH＝5的2mL MES溶液，加入30mg的EDC和20mg的NHS作为偶联剂在室温下活化激活1h，随后缓慢加入50mg的Au/Fe3O4@mSiO2/DOX-SS-PEG-NH2，调节PH至8，反应4h后离心，去离子水洗涤三次，即得多功能靶向药物控释分子探针Au/Fe3O4@mSiO2/DOX-SS-PEG-HA。
2.如权利要求1所述的一种兼具药物控释及成像功能的介孔氧化硅复合体的制备方法，其特征在于，含荧光(FITC)Au/Fe3O4@mSiO2-SH纳米颗粒，在加入MPTES时，同时加入0.1-0.2mL3-氨丙基三乙氧基硅烷(APTES)-异硫氰酸荧光素(FITC)反应前体。
3.如权利要求1所述的一种兼具药物控释及成像功能的介孔氧化硅复合体的制备方法，其特征在于，在步骤(1)中，氨水的质量分数28％。
4.如权利要求1所述的一种兼具药物控释及成像功能的介孔氧化硅复合体的制备方法，其特征在于，在步骤(1)中，TEOS乙醇溶液为0.2～0.3ml TEOS分散于20mL乙醇所形成的溶液。
CN202010584377.1A 2020-06-23 2020-06-23 兼具药物控释及成像功能的介孔氧化硅复合体的制备方法 Pending CN111701032A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010584377.1A CN111701032A (zh) 2020-06-23 2020-06-23 兼具药物控释及成像功能的介孔氧化硅复合体的制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010584377.1A CN111701032A (zh) 2020-06-23 2020-06-23 兼具药物控释及成像功能的介孔氧化硅复合体的制备方法

Publications (1)

Publication Number Publication Date
CN111701032A true CN111701032A (zh) 2020-09-25

Family

ID=72542443

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010584377.1A Pending CN111701032A (zh) 2020-06-23 2020-06-23 兼具药物控释及成像功能的介孔氧化硅复合体的制备方法

Country Status (1)

Country Link
CN (1) CN111701032A (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113292987A (zh) * 2021-05-26 2021-08-24 四川中科微纳科技有限公司 双发射金团簇比率荧光探针及其制备方法和强力霉素的检测方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103599751A (zh) * 2013-10-25 2014-02-26 浙江大学 巯基功能化磁性二氧化硅纳米材料的制备方法
CN108310388A (zh) * 2017-12-27 2018-07-24 湖北工业大学 二硫键功能化的荧光介孔二氧化硅纳米颗粒的制备方法及其用途
CN108671230A (zh) * 2018-05-17 2018-10-19 福州大学 一种金纳米壳磁性plga微胶囊及其制备方法
CN110559453A (zh) * 2019-10-15 2019-12-13 南京晓庄学院 一种用于显像指导的磁性纳米颗粒及其制备方法
CN110573145A (zh) * 2018-01-22 2019-12-13 北京茵诺医药科技有限公司 用于靶向活化cd44分子的介孔/中空二氧化硅纳米载体递送系统、其制备方法和用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103599751A (zh) * 2013-10-25 2014-02-26 浙江大学 巯基功能化磁性二氧化硅纳米材料的制备方法
CN108310388A (zh) * 2017-12-27 2018-07-24 湖北工业大学 二硫键功能化的荧光介孔二氧化硅纳米颗粒的制备方法及其用途
CN110573145A (zh) * 2018-01-22 2019-12-13 北京茵诺医药科技有限公司 用于靶向活化cd44分子的介孔/中空二氧化硅纳米载体递送系统、其制备方法和用途
CN108671230A (zh) * 2018-05-17 2018-10-19 福州大学 一种金纳米壳磁性plga微胶囊及其制备方法
CN110559453A (zh) * 2019-10-15 2019-12-13 南京晓庄学院 一种用于显像指导的磁性纳米颗粒及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
XIAOLIN LIU等: "Construction of magnetic-targeted and NIR irradiation-controlled drug delivery platform with Fe3O4@Au@SiO2 nanospheres", 《CERAMICS INTERNATIONAL》 *
金新天等: "透明质酸修饰的介孔二氧化硅包覆金纳米棒的制备及在肿瘤化疗-热疗联合治疗中的应用", 《高等学校化学学报》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113292987A (zh) * 2021-05-26 2021-08-24 四川中科微纳科技有限公司 双发射金团簇比率荧光探针及其制备方法和强力霉素的检测方法

Similar Documents

Publication Publication Date Title
Cai et al. Manganese oxide nanoparticles as MRI contrast agents in tumor multimodal imaging and therapy
Chen et al. NIR-II light activated photodynamic therapy with protein-capped gold nanoclusters
Zhao et al. Advanced nanotechnology for hypoxia-associated antitumor therapy
Xue et al. Stimuli‐responsive crosslinked nanomedicine for cancer treatment
Xu et al. Group IV nanodots: synthesis, surface engineering and application in bioimaging and biotherapy
Dou et al. Pb@ Au core–satellite multifunctional nanotheranostics for magnetic resonance and computed tomography imaging in vivo and synergetic photothermal and radiosensitive therapy
Wu et al. Mesoporous silica nanoparticles as nanocarriers
Chen et al. Recent advances of carbon dots in imaging-guided theranostics
Feng et al. Multifunctional UCNPs@ MnSiO 3@ gC 3 N 4 nanoplatform: improved ROS generation and reduced glutathione levels for highly efficient photodynamic therapy
Liu et al. Construction of smart manganese dioxide‐based all‐in‐one nanoplatform for cancer diagnosis and therapy
Zhu et al. An efficient tumor-inducible nanotheranostics for magnetic resonance imaging and enhanced photodynamic therapy
Zhai et al. Self-activated arsenic manganite nanohybrids for visible and synergistic thermo/immuno-arsenotherapy
Zhan et al. Intrinsically zirconium-89-labeled manganese oxide nanoparticles for in vivo dual-modality positron emission tomography and magnetic resonance imaging
CN103007303A (zh) 核-壳型三模态纳米造影剂、其制备方法及应用
Li et al. Multifunctional silica-based nanocomposites for cancer nanotheranostics
Li et al. Aptamer-directed specific drug delivery and magnetic resonance imaging of renal carcinoma cells in vitro and in vivo
US9849194B2 (en) Compositions and methods for imaging and treatment
Xu et al. Albumin-stabilized manganese-based nanocomposites with sensitive tumor microenvironment responsivity and their application for efficient SiRNA delivery in brain tumors
Mehravi et al. Breast cancer cells imaging by targeting methionine transporters with gadolinium-based nanoprobe
Ruan et al. Recent development on controlled synthesis of Mn‐based nanostructures for bioimaging and cancer therapy
Liang et al. Synthesis of NaYF4: Yb, Er upconversion nanoparticle-based optomagnetic multifunctional composite for drug delivery system
CN113577306B (zh) 一种双靶向、pH刺激响应的纳米粒子的制备及其在肿瘤诊疗中的应用
Lv et al. Multifunctional nanosnowflakes for T1-T2 double-contrast enhanced MRI and PAI guided oxygen self-supplementing effective anti-tumor therapy
Kang et al. Flexible human serum albumin nanocapsules to enhance drug delivery and cellular uptake for photodynamic/chemo cancer therapy
Liu et al. Intelligent albumin-stabilized manganese dioxide nanocomposites for tumor microenvironment responsive phototherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination